Clinipace Worldwide has completed the merger with Choice Pharma, a Pan-Asian CRO, extending its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia. According to the company, there are no layoffs or office closings planned. Terms of the transaction were not disclosed.

The combined company offers global clinical development services, along with product development, regulatory, and GxP/CMC/QA consultancy. Clinipace and Choice clients now have access to new markets for site activation and patient enrollment. Together, Clinipace will have more than 640 global staff with experience managing more than 1,500 clinical studies and 300 completed regulatory and strategic development engagements.

Chris Wang of Choice Pharma will continue to serve as managing director of Asian operations, reporting to Clinipace chief executive officer, Jeff Williams. “In order to continue to address the changing industry landscape and the high demand by clients for operations in Asia, we began the process of determining the best path for investing in the growth of our company, which led us to Choice Pharma,” said Mr. Williams, Clinipace Worldwide. “With complementary operational strengths, a great reputation for quality and an experienced management team, the decision to combine the two companies was the best solution to continue to meet the long-term strategic goals of clients on both sides.”

“A streamlined, efficient operational approach with real-time transparency that reduces cost and budget volatility is the future of clinical trials,” said Ms. Wang of Choice Pharma. “Not only can our clients leverage Clinipace’s dCRO delivery model, but they now have access to a comprehensive and integrated clinical operations, data management, biostatistics, and regulatory consultancy outside of Asia.”